KOREA ARLICO PHARM CO.,LTD. Logo

KOREA ARLICO PHARM CO.,LTD.

Manufactures generic drugs and provides CDMO services to a global market.

260660 | KO

Overview

Corporate Details

ISIN(s):
KR7260660006
LEI:
Country:
South Korea
Address:
서울특별시 서초구 바우뫼로27길 7-21 (양재동), 서초구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Korea Arlico Pharm Co., Ltd. is a pharmaceutical company engaged in the research, development, manufacturing, and sale of medicines. The company's operations are centered on the production and distribution of generic pharmaceuticals, including prescription (ETC) and over-the-counter (OTC) drugs, as well as a specialized Contract Development and Manufacturing Organization (CDMO) business for third-party clients. Its product portfolio addresses a range of therapeutic areas, including circulatory and digestive system disorders, anti-inflammatory analgesics, and hypertension. The company also develops and sells medical devices and active pharmaceutical ingredients. Operating from PIC/S GMP-certified facilities, Korea Arlico Pharm distributes its products in its domestic market and exports to numerous countries globally, positioning itself as a key domestic manufacturer with international reach.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 761.7 KB
2025-06-18 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 116.0 KB
2025-05-14 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 679.2 KB
2025-04-30 00:00
Regulatory News Service
소속부변경
Korean 3.6 KB
2025-03-28 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 21.8 KB
2025-03-20 00:00
Audit Report / Information
감사보고서제출
Korean 17.8 KB
2025-03-20 00:00
Annual Report
사업보고서 (2024.12)
Korean 1.1 MB
2025-03-06 00:00
Proxy Solicitation & Information Statement
의결권대리행사권유참고서류
Korean 83.6 KB
2025-02-26 00:00
Pre-Annual General Meeting Information
주주총회집중일개최사유신고
Korean 5.7 KB
2025-02-26 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 81.1 KB
2025-02-25 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 11.0 KB
2025-02-12 00:00
Earnings Release
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 11.3 KB
2025-02-12 00:00
Notice of Dividend Amount
현금ㆍ현물배당결정
Korean 9.1 KB
2024-12-17 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 127.6 KB
2024-12-13 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.1 KB

Automate Your Workflow. Get a real-time feed of all KOREA ARLICO PHARM CO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for KOREA ARLICO PHARM CO.,LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for KOREA ARLICO PHARM CO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Erasca, Inc. Logo
Clinical-stage oncology company developing therapies targeting the RAS/MAPK pathway in cancer.
United States of America
ERAS
Ernexa Therapeutics Inc. Logo
Developing targeted, off-the-shelf cell therapies for cancer and autoimmune diseases.
United States of America
ERNA
ERYTECH Pharma S.A. Logo
Developing phage therapies to combat antibiotic-resistant bacterial infections.
France
ERYP
Esperion Therapeutics, Inc. Logo
Develops oral ACLY inhibitors to lower high LDL-C and cardiovascular risk.
United States of America
ESPR
ESSA Pharma Inc. Logo
Develops novel small molecule drugs to treat castration-resistant prostate cancer.
United States of America
EPIX
Estrella Immunopharma, Inc. Logo
Clinical-stage biopharma developing ARTEMIS® T-cell therapies for cancer & autoimmune disease.
United States of America
ESLA
Eton Pharmaceuticals, Inc. Logo
Develops and commercializes innovative treatments for rare pediatric diseases.
United States of America
ETON
EuBiologics Co., Ltd. Logo
Develops vaccines for global public health and provides biopharmaceutical CRMO services.
South Korea
206650
EUPRAXIA PHARMACEUTICALS INC. Logo
Developing targeted, extended-release therapies for GI and musculoskeletal diseases.
United States of America
EPRX
EuroAPI Logo
Global manufacturer of APIs and CDMO services for human and animal health partners worldwide.
France
EAPI

Talk to a Data Expert

Have a question? We'll get back to you promptly.